Indapta Therapeutics
PrivateLast Round
VC Round
Dec 17, 2024
Total Funding Raised
$54.5M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Indapta Therapeutics is a biotechnology company developing a proprietary, off-the-shelf, allogeneic FcRγ-deficient natural killer (g-NK) cell therapy platform to treat cancer and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Government Contracts, Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Indapta Therapeutics Comparables
Compare Indapta Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Artiva | 87% | |
| Wugen | 86% | |
| CytoImmune Therapeutics | 85% |
Indapta Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Dec 17, 2024 | ||||
| Grant | May 15, 2024 | ||||
| Series A | Feb 10, 2022 |
Key People
Founding team and executive leadership
Indapta Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Cancer Prevention & Research Institute of Texas | Grant |
| RA Capital Management | VC Round, Series A |
| Vertex Ventures HC | VC Round, Series A |
| Pontifax Venture Capital | VC Round |
| Pontifax Credit | VC Round |
| Cancer Prevention and Research Institute of Texas | Grant |
| Leaps by Bayer | VC Round, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors grew 116% MoM.
- Jul 26, 2026
Monthly visitors increased 37% MoM.
Indapta Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Indapta Therapeutics's valuation, stock price, and market status.
Is Indapta a public or private company?
Indapta is a private company.
What is the current stock price of Indapta?
Indapta is a private company with no public stock price. No recent secondary market data is available.
How much is Indapta worth (valuation)?
Valuation information for Indapta is not publicly available.
Can I buy Indapta stock?
Indapta shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Indapta's last funding round?
Indapta's most recent funding round was Early Funding on December 17, 2024.
Who are the main investors in Indapta?
Key investors in Indapta include Cancer Prevention & Research Institute of Texas, RA Capital Management, Vertex Ventures HC, Cancer Prevention and Research Institute of Texas, Leaps by Bayer.
Will Indapta IPO soon?
No public IPO plans have been announced for Indapta.
How can I track Indapta secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Indapta's secondary market activity and sign up for updates.